cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.15468/dl.qzwwpz
title: Occurrence Download

description: A dataset containing 26 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Geometry POLYGON((-111.16825 35.20644,-108.68936 35.20644,-108.68936 36.37617,-111.16825 36.37617,-111.16825 35.20644))",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present",
 "TaxonKey is Sciurus aberti"
 ]
}

 The dataset includes 26 records from 5 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0039140-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15131/shef.data.30247105
title: A comparative life cycle assessment of conventional versus digital workflow for the fabrication of an all-ceramic crown

description: The data in this repository supports the conduct and findings of a Life Cycle Assessment (LCA) for the environmental impacts of conventional vs digital fabrication workflows for the provision of a ceramic tooth crown.This report identifies the key environmental impacts in a comparison between the digital and conventional workflow for the fabrication of a lithium disilicate and zirconia dental crown. Additional sensitivity analyses are performed in this life cycle assessment to evaluate how changes in the inputs can affect the results of the model and how we can optimise these outcomes to mitigate the environmental impact in the dental healthcare sector.
DOI: 10.15131/shef.data.30247105.v1
title: A comparative life cycle assessment of conventional versus digital workflow for the fabrication of an all-ceramic crown

description: The data in this repository supports the conduct and findings of a Life Cycle Assessment (LCA) for the environmental impacts of conventional vs digital fabrication workflows for the provision of a ceramic tooth crown.This report identifies the key environmental impacts in a comparison between the digital and conventional workflow for the fabrication of a lithium disilicate and zirconia dental crown. Additional sensitivity analyses are performed in this life cycle assessment to evaluate how changes in the inputs can affect the results of the model and how we can optimise these outcomes to mitigate the environmental impact in the dental healthcare sector.
DOI: 10.15468/dl.kweqhc
title: Occurrence Download

description: A dataset containing 18578 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is Canada",
 "GadmGid is CAN.11_1",
 "OccurrenceStatus is Present",
 "TaxonKey is Bombus"
 ]
}

 The dataset includes 18578 records from 40 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0039142-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.17026/ar/11o7xr
title: PAN-00121469 - coin/coin-related, Filips IV (1270-1314), double parisis

description: &lt;p&gt;This find is registered at Portable Antiquities of the Netherlands with number PAN-00121469&lt;/p&gt;
description: Modified: 2025-10-24T08:27:12+02:00
DOI: 10.25919/2vfs-kn26
title: Spatially balanced cluster design master sample for COTS and coral monitoring in the Great Barrier Reef

description: This data was produced as part of a COTS Control Innovation Program (CCIP) Translation project. The master sample is a spatially balanced sample of clusters of reefs where clusters have a 25km radius. The samples are stratified by Australian Institute of Marine Science (AIMS) Long Term Monitoring Program (LTMP) sector to ensure adequate representation across the reef. Within each sector clusters should be selected in order and reefs within those clusters should also be selected within order. The design requires the first logistically feasible reefs within each cluster to be monitored, if a reef is not able to be monitored for operational reasons eg. depth, crocodile risk, water visibility then the next reef on the list in that cluster should be selected. If a whole cluster is deemed an operational risk then the next cluster should be selected.
DOI: 10.15468/dl.d72c7b
title: Occurrence Download

description: A dataset containing 66 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Polydora limicola",
 "HasCoordinate is true",
 "HasGeospatialIssue is false"
 ]
}

 The dataset includes 66 records from 17 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0039144-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.fg46b6
title: Occurrence Download

description: A dataset containing 1109916 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is one of (Belgium, Germany, Netherlands)",
 "TaxonKey is one of (Ondatra zibethicus, Myocastor coypus)",
 "OccurrenceStatus is Present"
 ]
}

 The dataset includes 1109916 records from 80 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0039128-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5281/zenodo.17860933
title: PubMed-Temporal: A dynamic graph dataset with node-level features
DOI: 10.5281/zenodo.13932075
title: PubMed-Temporal: A dynamic graph dataset with node-level features
DOI: 10.25934/pr00009492
title: Understanding frailty, multimorbidity and renal failure in clinical trials: Attrition, retention and heterogeneity of treatment effects in trials for diabetes, cancer and a heterogenous set of index conditions

description: Clinical trials are the key method for determining treatment effects, but are known to be unrepresentative with respect to a range of important clinical characteristics such as age, kidney function, race/ethnicity, multimorbidity and frailty. Declining kidney function is associated both with increasing age and multimorbidity and has important additional implications for drug selection and dosing which are not adequately considered in the clinical trial setting.

We have previously made a number of important observations regarding trials and representativeness. First, multimorbidity and frailty are present (albeit underrepresented) in clinical trials and both predict serious adverse event rates (Hanlon 2019, Hanlon 2021 and Hanlon 2022). Secondly, morbidity count (a metric of multimorbidity) is not associated with heterogeneity in treatment effects (File attachments), but is associated with increased rates of trial attrition (failure for any reason to complete the final trial visit, including intentional and non-intentional withdrawals) (Lees 2022). Finally, clinical trials can be calibrated to real-world populations in order to improve the representativeness of trial findings (Butterly 2022).

However, while these findings are novel, they are difficult to operationalise. We intend to take these findings in three directions. First, we wish to better understand the relationship between frailty and kidney function and trial outcomes and characteristics. Secondly, we wish to determine whether it is practical to increase trial representativeness by recruiting more individuals with frailty, multimorbidity and impaired kidney function, or whether this would simply lead to greater trial attrition. Thirdly, we wish to determine whether calibrating trials to target populations modifies treatment effects, and whether the magnitude of this differs depending on the level of frailty, multimorbidity and kidney function within each trial.

We propose addressing these questions using two specific exemplars: 1. Novel antidiabetics for type 2 diabetes (see this protocol document for a description of the trials); 2. Cancer drugs for 4 common cancer sites: kidney/renal tract, colorectal, lung and melanoma. Where feasible (e.g. for the attrition risk prediction scores (the probability that an individual will experience trial attrition)) we will also validate the findings against the heterogeneous set of trials (21 index conditions across general medicine) which we have already extensively studied and for which we have considerable R code within the Vivli repository.
DOI: 10.25934/00000167
title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 14 Days in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis

description: The purpose of the study is to compare the efficacy and safety of an investigational nasal spray compared with placebo nasal spray in the treatment of seasonal allergic rhinitis. Allergic rhinitis is an inflammatory disorder of the upper airway that occurs following allergen exposure. The focus of this study, seasonal allergic rhinitis (SAR), is one type of allergic rhinitis that is triggered by the pollen from trees, grasses, and weeds. Commonly referred to as "hay fever", it is characterized by sneezing, nasal congestion and pruritus, rhinorrhea, and pruritic, watery, red eyes.
DOI: 10.25934/00000181
title: A Randomized, Double-blind, Positive-Controlled, Multicenter Study Comparing the Efficacy of Carvedilol Phosphate Modified Release Formulation (COREG MR) and Metoprolol Succinate Extended Release (TOPROL-XL) on the Reduction of Microalbuminuria in Patients With Hypertension and Microalbuminuria

description: This study was designed to determine whether COREG MR is more effective than TOPROL-XL in reducing microalbuminuria in type 2 diabetic or non-diabetic patients with high blood pressure and microalbuminuria.
DOI: 10.25934/00000227
title: A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole XR (Extended Release) in Patients With Restless Legs Syndrome

description: The purpose of this study is to assess the efficacy and safety of ropinirole XR in the treatment of adults with Restless Legs Syndrome (RLS).
DOI: 10.25934/00000312
title: A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)

description: Restless Legs Syndrome (RLS) study in adults comparing immediate release ropinirole with extended release ropinirole over 12 weeks
DOI: 10.25934/00000732
title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Two Dose Levels of Albiglutide Compared With Placebo in Subjects With Type 2 Diabetes Mellitus

description: The purpose of this study is to determine whether albiglutide is effective in the treament of patients with type 2 diabetes.
DOI: 10.25934/00001017
title: A Multicenter Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GW642444 and With Tiotropium Over 24 Weeks in Subjects With COPD

description: This is a Phase III multicenter, randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of two doses of GSK573719/GW642444 Inhalation Powder and GW642444 Inhalation Powder via a Novel Dry Powder Inhaler and tiotropium via HandiHaler when administered once-daily over a 24-week treatment period in subjects with chronic obstructive pulmonary disease (COPD). Subjects who meet eligibility criteria at Screening (Visit 1) will complete a 7 to10 day run-in period followed by a randomization visit (Visit 2) then a 24-week treatment period. There will be a total of 9 clinic study visits. A follow-up phone contact for adverse event assessment will be conducted approximately one week after the last study visit (Visit 9 or Early Withdrawal). The total duration of subject participation in the study will be approximately 26 weeks. The primary measure of efficacy is clinic visit trough (pre-bronchodilator and pre-dose) forced expiratory volume in one second (FEV1) on Treatment Day 169. Safety will be assessed by adverse events, 12-lead ECGs, vital signs, and clinical laboratory tests.
DOI: 10.25934/00001018
title: A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD

description: This is a Phase III multicenter, randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of two doses of GSK573719/GW642444 Inhalation Powder, GSK573719 Inhalation Powder via a Novel Dry Powder Inhaler and tiotropium via HandiHaler when administered once-daily over a 24-week treatment period in subjects with chronic obstructive pulmonary disease (COPD). Subjects who meet eligibility criteria at Screening (Visit 1) will complete a 7 to10 day run-in period followed by a randomization visit (Visit 2) then a 24-week treatment period. There will be a total of 9 clinic study visits. A follow-up phone contact for adverse event assessment will be conducted approximately one week after the last study visit (Visit 9 or Early Withdrawal). The total duration of subject participation in the study will be approximately 26 weeks. The primary measure of efficacy is clinic visit trough (pre-bronchodilator and pre-dose) forced expiratory volume in one second (FEV1) on Treatment Day 169. Safety will be assessed by adverse events, 12-lead ECGs, vital signs, and clinical laboratory tests.
DOI: 10.25934/00001432
title: Open Label, Randomised, Parallel Group, Multicentre, Ph III Study To Assess Efficacy, Safety & Tolerability Of Gefitinib (IRESSA™) Versus Carboplatin/Paclitaxel DC As 1st-Line Treatment In Selected Patients With Stage IIIB / IV NSCLC In Asia

description: The purpose of this study is to compare gefitinib with carboplatin / paclitaxel doublet chemotherapy given as first line treatment in terms of progression free survival in selected NSCLC patients with the objective of demonstrating non-inferiority.
DOI: 10.25934/00002058
title: A 54-week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) as Adjunctive Therapy to Donepezil on Cognition and Overall Clinical Response in APOE ε4-stratified Subjects With Mild to Moderate Alzheimer's Disease.

description: Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer's disease (AD) when combined with the currently approved AD medication, Aricept (donepezil). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one's genetic makeup affects their response to the study drug. Clinical data suggesting that RSG may benefit AD patients was first seen in a small study performed at the University of Washington and then from a larger GSK study conducted in Europe and New Zealand. In the first study, subjects receiving RSG once daily for 6 months scored significantly better on 3 tests of memory and thought than those who did not receive RSG. In the GSK study, those that appeared to benefit most from treatment with RSG XR had a specific genetic pattern. They did not have the gene that caused them to produce the protein apolipoprotein E e4 (APOE e4). Subjects who have the APOE e4 gene may have two copies, one from each parent, or they may have only one APOE e4 gene meaning that they inherited either the APOE e2 or APOE e3 version of the gene, instead of APOE e4, from one of their parents. Subjects with one copy of the APOE e4 gene remained at their same level of thinking ability while those with two copies of the APOE e4 gene, continued to worsen during the 6-month treatment. The current study will more directly test the effectiveness or RSG XR on people who either have or lack the APOE e4 gene.
DOI: 10.25934/00003278
title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study to Evaluate the Safety and Efficacy of SYR-472 When Orally Administered at a Dose of 100 mg Once Weekly as an add-on to Insulin Therapy in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Treatment With Insulin Preparations in Addition to Diet and/or Exercise Therapy

description: The purpose of this study is to evaluate the efficacy and safety of SYR-472 when administered at a dose of 100 mg once weekly as an add-on to insulin therapy (SYR-472 100 mg combination/SYR-472 100 mg combination group) using insulin preparation alone/ SYR-472 100 mg combination group as a control in patients with type 2 diabetes mellitus and inadequate glycemic control despite treatment with insulin preparations in addition to diet and/or exercise therapy; and to evaluate the long-term efficacy and safety of SYR-472 when administered at a dose of 100 mg once weekly as an add-on to insulin therapy in patients with type 2 diabetes mellitus and inadequate glycemic control despite treatment with insulin preparations in addition to diet and/or exercise therapy.
DOI: 10.25934/00003374
title: A Prospective, Randomized, Double-Blind, Forced Titration Trial to Compare the Efficacy of MICARDIS® (Telmisartan 80 mg p.o. Once Daily) and Diovan® (Valsartan 160 mg p.o. Once Daily) Using Ambulatory Blood Pressure Monitoring (ABPM) in Patients With Mild to Moderate Hypertension After Missing One Dose

description: The primary objectives are to demonstrate that MICARDIS® (telmisartan) is statistically superior to Diovan® (valsartan) in reducing diastolic blood pressure (DBP) following a missed dose at the end of a 6 to 8-week treatment period as measured by the 24-hour ABPM mean and to demonstrate that MICARDIS® is statistically superior to Diovan® in reducing DBP during the last 6-hours of the 24-hour dosing interval as measured by ABPM following a dose of active study medication at the end of a 6 to 8-week treatment period.
DOI: 10.25934/00003402
title: A 12-week Randomised, Double Blind, Placebo Controlled, Parallel Group Trial Evaluating the Efficacy and Safety of Inhaled Tiotropium 18μg q.d. in Patients With COPD and a Concomitant Diagnosis of Asthma

description: The primary objective of this study is to demonstrate the superiority of tiotropium compared to placebo in the treatment of patients with COPD and a concomitant diagnosis of asthma
DOI: 10.25934/00003404
title: A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Investigate the Efficacy of Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy VIVALDI-Study

description: The general aim of this study is to compare telmisartan 80 mg with valsartan 160 mg in hypertensive patients with type 2 diabetes and overt nephropathy with adjusted blood pressure beyond the target of 130/80 mmHg after one year of treatment. The primary objective of this study is to show that telmisartan 80 mg is at least as effective (i.e., not inferior) and possibly superior to valsartan 160 mg in reducing 24 hour proteinuria after one year of treatment.
DOI: 10.15468/dl.a7nfem
title: Occurrence Download

description: A dataset listing the 1 species recorded in GBIF matching the query:
{
 "TaxonKey" : [
 "is Burmagomphus chaukulensis Joshi, Ogale & Sawant, 2022"
 ]
}

 The dataset's 1 records were derived from 2 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0005404-230828120925497/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.avbxj4
title: Occurrence Download

description: A dataset containing 10 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Schaueria macrophylla Pohl ex Nees"
 ]
}

 The dataset includes 10 records from 6 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0192076-240321170329656/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.17630/2898c6e7-00ba-44fe-9ca2-cb08501a6bca
title: Data underpinning - Ultrafast Band Structure Control of a Two-Dimensional Heterostructure

description: Data underpinning publication
DOI: 10.15468/dl.jfl0oh
title: Occurrence Download

description: A dataset containing 31122 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Tockus erythrorhynchus (Temminck, 1823)"
 ]
}

 The dataset includes 31122 records from 87 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0036606-191105090559680/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.mkz7gu
title: Occurrence Download

description: A dataset containing 79 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Puma concolor (Linnaeus, 1771)",
 "Country is Colombia"
 ]
}

 The dataset includes 79 records from 23 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0002503-170714134226665/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.vf6qb9
title: Occurrence Download

description: A dataset containing 13966421 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is Brazil",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present",
 "TaxonKey is Aves"
 ]
}

 The dataset includes 13966421 records from 114 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0014066-240202131308920/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.0e1jdj
title: Occurrence Download

description: A dataset containing 59 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Lagothrix flavicauda (Humboldt, 1812)"
 ]
}

 The dataset includes 59 records from 6 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0002503-170925132151566/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.ukykze
title: Occurrence Download

description: A dataset containing 195 species occurrences available in GBIF matching the query:
{
 "and" : [
 "BasisOfRecord is Human Observation",
 "Country is India",
 "Geometry POLYGON((69.30175 7.17192,89.29961 7.17192,89.29961 31.50747,69.30175 31.50747,69.30175 7.17192))",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present",
 "TaxonKey is Echis carinatus (Schneider, 1801)"
 ]
}

 The dataset includes 195 records from 2 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0013197-220831081235567/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.b2u6sj
title: Occurrence Download

description: A dataset containing 2312 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is Netherlands",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present",
 "TaxonKey is Anthocharis cardamines (Linnaeus, 1758)",
 "Year 1970-2000"
 ]
}

 The dataset includes 2312 records from 7 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0046412-210914110416597/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.